<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02018198</url>
  </required_header>
  <id_info>
    <org_study_id>13-0830</org_study_id>
    <nct_id>NCT02018198</nct_id>
  </id_info>
  <brief_title>FebriDx DISRUPT Acute Respiratory Infection Trial in Acute Respiratory Infection: An Evaluation of FebriDx® POC Test</brief_title>
  <official_title>DIStinguish Respiratory Underlying Pathogen associaTed Host Response in Acute Respiratory Infection: An Evaluation of FebriDx POC Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rapid Pathogen Screening</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rapid Pathogen Screening</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine performance characteristics of the FebriDx test in
      predicting viral or bacterial infection etiology among febrile (observed or reported)
      patients presenting the emergency department, urgent care centers or primary care offices
      with suspected acute respiratory tract infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, observational, blinded clinical trial whereby consented
      study subjects will be enrolled into two study cohorts: an Acute Respiratory Infection cohort
      and an Asymptomatic cohort. Subjects (children/adolescents, adults and elderly) with
      suspected community acquired Acute Respiratory Infection will be enrolled in the Acute
      Respiratory Infection cohort and subjects without infectious illness will be enrolled in the
      Asymptomatic cohort. All subjects will undergo FebriDx testing (study device) and results,
      blinded to subjects and treating physicians, will be compared to a Clinical Reference
      Algorithm supervised by clinical experts to arbitrate the presence and type of infection
      (bacterial or viral); the experts are also blinded to the results of FebriDx testing.

      The FebriDx® test is a rapid, point-of-care (POC) test that uses a fingerstick blood sample
      to identify patients with a pathogen induced host immune response through in-vitro detection
      of both Myxovirus resistance protein A (MxA) and c-reactive protein (CRP) directly from a
      whole blood sample. MxA is an intracellular protein that becomes elevated in the presence of
      acute viral infection and CRP is an acute-phase inflammatory protein that is elevated in the
      presence of a systemic bacterial and/or viral infection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is the presence of a bacterial associated systemic host immune response or viral associated systemic host immune response related to an acute community acquired febrile acute respiratory tract infection, as compared to final diagnosis</measure>
    <time_frame>10 minutes</time_frame>
    <description>The primary analysis will determine performance characteristics of the FebriDx® test by assessing negative and positive agreement of the FebriDx® results in determining the presence of a bacterial associated systemic host immune response or viral associated systemic host immune response compared with a Clinical Reference Algorithm (comparator method) that is supervised by clinical experts.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Acute Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>Acute Respiratory Infection</arm_group_label>
    <description>Study subjects will be 1 year of age and older presenting to emergency departments, urgent care centers and primary care offices with a new onset, measured fever and new onset respiratory symptoms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymptomatic Cohort</arm_group_label>
    <description>Study subjects will be 1 year of age and older presenting to emergency departments, urgent care centers and primary care offices without infection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FebriDx</intervention_name>
    <description>Point of Care Host Immune Response Test</description>
    <arm_group_label>Acute Respiratory Infection</arm_group_label>
    <arm_group_label>Asymptomatic Cohort</arm_group_label>
  </intervention>
  <biospec_descr>
    <textblock>
      Respiratory and blood specimens will be retained for future testing.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting with a new onset, measured fever (exhibited or reported) and acute
        respiratory symptoms
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Acute Respiratory Infection Cohort INCLUSION CRITERIA

          -  1 year of age or older

          -  Exhibit or report of a new onset measured temperature (oral or tympanic) of greater
             than or equal to 100.5°F/38°C within 3 days (72 hours) of enrollment

          -  Clinical suspicion for Acute Respiratory Infection and presents with at least one of
             the following new onset of symptoms: runny nose, nasal congestion, sore throat, cough,
             hoarse voice or shortness of breath beginning within 7 days before enrollment

        Acute Respiratory Infection Cohort EXCLUSION CRITERIA

          -  Incomplete or invalid testing for comparator method

          -  Unwilling to participate

          -  Receiving interferon therapy (e.g. MS, HIV, HBV, HCV) in the last 30 days

          -  Immunocompromised state (e.g. HIV) or taking immunosuppressive or chemotherapeutic
             medications in the last 30 days (e.g. oral steroids, Methotrexate, Cyclosporine,
             Antimetabolite chemotherapy, interferon therapy)

          -  Taking antibiotics or antiviral therapy in the last 14 days

          -  Received a live viral immunization in the last 14 days

          -  Significant trauma or burns (&gt; 5% total body surface area or full thickness (3rd°)) in
             the last 30 days

          -  Major surgery (requiring intravenous anesthesia and/or respiratory assistance) in the
             last 30 days

          -  Chronic fever without associated respiratory symptoms of greater than 7 days

          -  History of ear pain plus an exam consistent with otitis media within the last 14 days

          -  History of a myocardial infarction or stroke in the last 30 days

        ASYMPTOMATIC COHORT INCLUSION CRITERIA

          -  1 year of age or older

          -  Absence of infectious signs and symptoms

        ASYMPTOMATIC COHORT EXCLUSION CRITERIA

          -  Fever greater than or equal to 100.5°F /38°C (oral or tympanic) in last 14 days

          -  Cough

          -  Chills

          -  Dyspnea

          -  Purulent Sputum

          -  Fatigue

          -  Pleuritic Pain

          -  Nasal congestion

          -  Rhinorrhea (runny nose)

          -  Sore throat

          -  Hoarse voice

          -  Earache

          -  Autoimmune or rheumatologic disease (e.g. undifferentiated connective tissue disease,
             Rheumatoid Arthritis, Systemic Lupus Erythematosus (and subsets of Lupus), Sjögren's
             syndrome, Systemic Sclerosis, Polymyositis and Dermatomyositis, Wegener's
             granulomatosis)

          -  Suspected of having any infection

          -  Receiving interferon therapy (e.g. MS, HIV, HBV, HCV) in last 30 days

          -  Immunocompromised state (e.g. HIV) or taking immunosuppressive (e.g. oral steroids,
             Methotrexate, Cyclosporine, Antimetabolite chemotherapy, interferon therapy) in the
             last 30 days

          -  Taking antibiotics or antiviral therapy in the last 30 days

          -  Received a live viral immunization in the last 30 days

          -  Significant trauma or burns (&gt; 5% total body surface area or full thickness (3rd°)) in
             the last 30 days

          -  Major surgery (requiring intravenous anesthesia and/or respiratory assistance) in the
             last 30 days

          -  History of a myocardial infarction or stroke in the last 30 days

          -  Chronic bacterial infection or osteomyelitis

          -  Known chronic viral infections such as HIV, HCV, HBV, or CMV

          -  Active tuberculosis

          -  Acute or chronic (greater than 30 days) diarrhea and/or vomiting

          -  Urinary tract symptoms in the last 14 days

          -  Active diarrheal illness within the last 14 days

          -  Active skin, ocular, or neurologic infections

          -  Suspected of having otitis media
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathan Shapiro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annie Bell, MSN, APN</last_name>
    <phone>(773)729-8954</phone>
    <email>annie.bell@lumosdiagnostics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rob Sambursky, MD</last_name>
    <phone>(941) 556-1853</phone>
    <email>rob.sambursky@lumosdiagnostics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AFC Urgent Care/Urgent Care Clinical Trials</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Palm</last_name>
    </contact>
    <investigator>
      <last_name>Johnny Shen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Shapiro, MD</last_name>
      <email>nshapiro@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Nathan Shapiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Methodist Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Birkhahn, MD</last_name>
    </contact>
    <investigator>
      <last_name>Robert Birkhahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Woodruff Road Urgent Care Center/Urgent Care Clinical Trials</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Parsons</last_name>
    </contact>
    <investigator>
      <last_name>Jeffrey Harris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkside Pediatrics</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayla Puck, MD</last_name>
      <email>KPuck@tribe513.org</email>
    </contact>
    <investigator>
      <last_name>Scott R. Dobson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Woodruff Road Urgent Care Center, P.C./ Urgent Care Clinical Trials</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Parsons</last_name>
    </contact>
    <investigator>
      <last_name>Jeffrey Harris, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AFC Urgent Care/Urgent Care Clinical Trials</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosetta Loeser</last_name>
    </contact>
    <investigator>
      <last_name>Natasha Ballard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Schipani</last_name>
      <email>cralms@aol.com</email>
    </contact>
    <investigator>
      <last_name>Stephan C Sharp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA Office of Research and Development/Vanderbilt University School of Medicine</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CityDoc Urgent Care/Urgent Care Clinical Trials</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brook Jackson</last_name>
    </contact>
    <investigator>
      <last_name>Shiwali Rai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyza Guerrero</last_name>
      <email>elyzaguerrero@benchmarkresearch.net</email>
    </contact>
    <investigator>
      <last_name>Darrell Herrington, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison/Berbee Walsh Department of Emergency Medicine</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Joseph P, Godofsky E. Outpatient Antibiotic Stewardship: A Growing Frontier-Combining Myxovirus Resistance Protein A With Other Biomarkers to Improve Antibiotic Use. Open Forum Infect Dis. 2018 Feb 15;5(2):ofy024. doi: 10.1093/ofid/ofy024. eCollection 2018 Feb.</citation>
    <PMID>29479553</PMID>
  </results_reference>
  <results_reference>
    <citation>Shapiro NI, Self WH, Rosen J, Sharp SC, Filbin MR, Hou PC, Parekh AD, Kurz MC, Sambursky R. A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever. Ann Med. 2018 Aug;50(5):420-429. doi: 10.1080/07853890.2018.1474002. Epub 2018 May 18.</citation>
    <PMID>29775092</PMID>
  </results_reference>
  <results_reference>
    <citation>Self WH, Rosen J, Sharp SC, Filbin MR, Hou PC, Parekh AD, Kurz MC, Shapiro NI. Diagnostic Accuracy of FebriDx: A Rapid Test to Detect Immune Responses to Viral and Bacterial Upper Respiratory Infections. J Clin Med. 2017 Oct 7;6(10). pii: E94. doi: 10.3390/jcm6100094.</citation>
    <PMID>28991170</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>December 17, 2013</study_first_submitted>
  <study_first_submitted_qc>December 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2013</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Host Immune Response</keyword>
  <keyword>Biomarker</keyword>
  <keyword>Point-of-Care</keyword>
  <keyword>Myxovirus Resistance Protein A (MxA)</keyword>
  <keyword>C-reactive Protein (CRP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

